药学与临床研究2024,Vol.32Issue(2) :160-164.

硫酸黏菌素联合治疗ICU内广泛耐药革兰阴性杆菌感染的疗效与安全性

Efficacy and Safety of Colistin Sulfate Combined Therapy for Extensively Drug Resistant Gram-negative Bacteria Infection in ICU

王瑰 薛晓燕 钱亚芳 陈荣 包万员 毛易捷
药学与临床研究2024,Vol.32Issue(2) :160-164.

硫酸黏菌素联合治疗ICU内广泛耐药革兰阴性杆菌感染的疗效与安全性

Efficacy and Safety of Colistin Sulfate Combined Therapy for Extensively Drug Resistant Gram-negative Bacteria Infection in ICU

王瑰 1薛晓燕 2钱亚芳 2陈荣 2包万员 1毛易捷3
扫码查看

作者信息

  • 1. 常州市第一人民医院重症医学科,常州 213003
  • 2. 常州市第一人民医院药学部,常州 213003
  • 3. 常州市第一人民医院医学检验科,常州 213003
  • 折叠

摘要

目的:评价硫酸黏菌素治疗ICU内广泛耐药(XDR)革兰阴性杆菌感染的疗效与安全性.方法:纳入我院ICU收治的XDR革兰阴性杆菌感染并使用硫酸黏菌素治疗的患者,收集其目标病原菌、联合用药方案、给药方式及剂量等,观察和评估其疗效与不良反应.结果:使用硫酸黏菌素联合抗感染治疗的患者共109例,临床有效68例(62.4%);细菌学清除65例(59.6%);发生肾损伤不良反应3例(2.8%),其中1例为很可能,2例为可能.结论:对于XDR革兰阴性杆菌感染的重症患者,以硫酸黏菌素为基础的联合抗感染方案具有较好的疗效,雾化吸入安全性较高,但仍需关注其肾损伤可能的不良反应.

Abstract

Objective:To evaluate the efficacy and safety of colistin sulfate in the treatment of exten-sively drug resistant(XDR)gram-negative bacteria infection in ICU.Methods:For patients with XDR gram-negative bacteria infection treated with colistin sulfate in the ICU of our hospital,the target pathogen,combined drug regimen,administration method and dose were collected,and their efficacy and adverse re-actions were observed and evaluated.Results:A total of 109 patients were treated with colistin sulfate combined anti infection,68 cases(62.4%)were clinically effective;65 cases(59.6%)were bacteriologically clearance;and 3 cases(2.8%)of adverse reactions of kidney injury,1 case was probably,2 cases were possibly.Conclusions:For severe patients with XDR gram-negative bacteria infection,the combined anti infection regimen containing colistin sulfate has good efficacy and high safety,but it is still necessary to pay attention to the possible adverse reactions of renal injury.

关键词

硫酸黏菌素/联合抗感染方案/广泛耐药革兰阴性杆菌/疗效/安全性

Key words

Colistin sulfate/Combined anti infection regimen/Extensively drug resistant gram-negative bacteria/Efficacy/Safety

引用本文复制引用

基金项目

常州市科技计划应用基础研究指导性项目(第十四批)(CJ20219031)

江苏省药学会-恒瑞医院药学基金科研项目(H202146)

出版年

2024
药学与临床研究
江苏省药学会

药学与临床研究

CSTPCD
影响因子:0.95
ISSN:1673-7806
参考文献量18
段落导航相关论文